.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB05_Apalutamide.Apalutamide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB05_Apalutamide.Apalutamide| name: | Apalutamide |
| ATC code: | L02BB05 | route: | oral |
| n-compartments | 2 |
Apalutamide is a non-steroidal androgen receptor inhibitor indicated for the treatment of prostate cancer, specifically non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is approved and used in clinical practice as an oral therapy.
Pharmacokinetic parameters reported for adult male patients with prostate cancer after repeated once-daily oral dosing at the recommended clinical dose.
Pérez-Ruixo, C, et al., & Ackaert, O (2020). Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects. Clinical pharmacokinetics 59(2) 229–244. DOI:10.1007/s40262-019-00808-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31432469
Leblanc, K, et al., & Emmenegger, U (2024). Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus. Cancers 16(19) –. DOI:10.3390/cancers16193336 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39409956